Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer
Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encou...
Saved in:
| Published in | BMC medicine Vol. 15; no. 1; p. 118 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
26.06.2017
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification.
We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint.
The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10
; hazard ratio (HR) 37.9, 95% confidence interval 4.1-353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044).
This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. |
|---|---|
| AbstractList | Background Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. Methods We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint. Results The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10−7; hazard ratio (HR) 37.9, 95% confidence interval 4.1-353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044). Conclusions This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. Abstract Background Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. Methods We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint. Results The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10−7; hazard ratio (HR) 37.9, 95% confidence interval 4.1–353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044). Conclusions This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint. The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10 ; hazard ratio (HR) 37.9, 95% confidence interval 4.1-353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044). This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. BACKGROUNDMetastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. METHODSWe investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint. RESULTSThe optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 × 10-7; hazard ratio (HR) 37.9, 95% confidence interval 4.1-353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044). CONCLUSIONSThis case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. Background Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. Methods We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint. Results The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 x 10.sup.-7; hazard ratio (HR) 37.9, 95% confidence interval 4.1-353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044). Conclusions This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. Keywords: Cancer, Tumour heterogeneity, Prognostic markers, Renal cell carcinoma, Tumour biomarkers Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk stratification has sought to overcome the performance ceiling encountered by methods restricted to traditional clinical parameters. However, replication of results has proven challenging, and intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. We investigated the influence of confounding ITH on the performance of a novel molecular prognostic model, enabled by pathologist-guided multiregion sampling (n = 183) of geographically separated mccRCC cohorts from the SuMR trial (development, n = 22) and the SCOTRRCC study (validation, n = 22). Tumour protein levels quantified by reverse phase protein array (RPPA) were investigated alongside clinical variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall survival as the primary endpoint. The optimal subset of variables in the final stratification model consisted of N-cadherin, EPCAM, Age, mTOR (NEAT). Risk groups from NEAT had a markedly different prognosis in the validation cohort (log-rank p = 7.62 x 10.sup.-7; hazard ratio (HR) 37.9, 95% confidence interval 4.1-353.8) and 2-year survival rates (accuracy = 82%, Matthews correlation coefficient = 0.62). Comparisons with established clinico-pathological scores suggest favourable performance for NEAT (Net reclassification improvement 7.1% vs International Metastatic Database Consortium score, 25.4% vs Memorial Sloan Kettering Cancer Center score). Limitations include the relatively small cohorts and associated wide confidence intervals on predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, sample selection could change risk group assignment for 64% of patients, and prognostication with one sample per patient performed only slightly better than random expectation (median logHR = 0.109). Low grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p = 0.044). This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable parameters to guide sample collection (tumour coverage, size, grade) to inform the development of reproducible molecular risk stratification methods. |
| ArticleNumber | 118 |
| Audience | Academic |
| Author | Mullen, Peter Harrison, David J O'Donnell, Marie Stewart, Grant D Overton, Ian M Laird, Alexander Lubbock, Alexander L R O'Mahony, Fiach C Powles, Thomas |
| Author_xml | – sequence: 1 givenname: Alexander L R surname: Lubbock fullname: Lubbock, Alexander L R organization: Present Address: Vanderbilt University School of Medicine, Vanderbilt University, Nashville, Tennessee, USA – sequence: 2 givenname: Grant D surname: Stewart fullname: Stewart, Grant D organization: Present Address: Academic Urology Group, University of Cambridge, Box 43, Addenbrooke's Hospital, Cambridge Biomedical Campus, Hill's Road, Cambridge, CB2 0QQ, UK – sequence: 3 givenname: Fiach C surname: O'Mahony fullname: O'Mahony, Fiach C organization: Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC), Scotland, UK – sequence: 4 givenname: Alexander surname: Laird fullname: Laird, Alexander organization: Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC), Scotland, UK – sequence: 5 givenname: Peter surname: Mullen fullname: Mullen, Peter organization: School of Medicine, University of St Andrews, St Andrews, Fife, KY16 9TF, UK – sequence: 6 givenname: Marie surname: O'Donnell fullname: O'Donnell, Marie organization: Department of Pathology, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 7 givenname: Thomas surname: Powles fullname: Powles, Thomas organization: Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, EC1M 6BQ, UK – sequence: 8 givenname: David J surname: Harrison fullname: Harrison, David J organization: School of Medicine, University of St Andrews, St Andrews, Fife, KY16 9TF, UK – sequence: 9 givenname: Ian M surname: Overton fullname: Overton, Ian M email: ian.overton@ed.ac.uk, ian.overton@ed.ac.uk organization: Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH16 4UX, UK. ian.overton@ed.ac.uk |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28648142$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUttq3DAQNSWlubQf0JdiKJS-ONVYlmX3IRBCL4FAXtpnoctoVxtb2kp2YB_675W7aZotRaDLzDln0Mw5LY588FgUr4GcA3TthwR1D21FgFek403VPytOgDdQcQLs6Mn9uDhNaUNIzThvXhTHddc2HTT1SfHz9h6jDqPzq9L5KcppHsMc5VCuccIYVujRTbvShlhG3MZgZu3UgOUYBtTzIHPYpbsyLVRnnc578B9LWWqZMIdns8vCpTT30ms05Z0zHnc5m1_xZfHcyiHhq4fzrPj--dO3q6_Vze2X66vLm0qzHqYKLPa2M5JRsLyFXkFjuFFEU6OkooqiUh1o2YHStZGtNh2liITaBizrW3pWXO91TZAbsY1ulHEngnTidyDElZBxcnpAIWVPlGa8sSSzJShQ2GuJNasJMTXNWhd7re2sRjQal64NB6KHGe_WYhXuBWs62lGeBd4_CMTwY8Y0idEljcMgPYY5Cegh4ygwlqFv_4Fu8nB8btWCYnXbc979Ra1k_oDzNuS6ehEVlwyAtnVTL2XP_4PKy-DodDaWdTl-QHj3hLBGOUzrFIZ5GXA6BMIeqGNIKaJ9bAYQsRhV7I0qslHFYlTRZ86bp118ZPxxJv0FIpTnjA |
| CitedBy_id | crossref_primary_10_1186_s12916_018_1088_5 crossref_primary_10_3390_diagnostics13132294 crossref_primary_10_1136_jclinpath_2018_205456 crossref_primary_10_1093_bioinformatics_btaa056 crossref_primary_10_1186_s12885_021_08965_4 |
| Cites_doi | 10.1200/JCO.2008.21.4809 10.1002/sim.1802 10.1158/0008-5472.CAN-09-2211 10.1200/JCO.2008.20.1293 10.1016/j.eururo.2014.06.053 10.1038/sj.bjc.6604921 10.1056/NEJMoa065044 10.1038/ng.2891 10.1038/nrc3261 10.1214/aos/1013699998 10.1016/S1470-2045(12)70559-4 10.1007/s10549-015-3654-2 10.1111/j.2517-6161.1972.tb00899.x 10.1093/jnci/djp335 10.1016/j.eururo.2015.01.005 10.1016/j.eururo.2006.10.025 10.1016/j.yexcr.2005.09.019 10.1136/jcp.2011.090274 10.1007/s12325-011-0099-9 10.1002/cncr.29224 10.1158/0008-5472.CAN-12-3232 10.1016/j.urolonc.2014.11.009 10.1016/S1470-2045(12)70581-8 10.1016/j.surge.2015.03.001 10.1016/j.cell.2012.03.017 10.1038/bjc.2012.581 10.1016/j.eururo.2010.10.029 10.1097/01.ju.0000125487.96469.2e 10.3791/50221 10.1016/j.eururo.2014.04.007 10.1158/1078-0432.CCR-15-0207 10.2353/ajpath.2007.070152 10.1200/JCO.2005.05.179 10.1038/nrurol.2011.43 10.1097/EDE.0000000000000018 10.1186/s13059-015-0620-6 10.1002/ijc.27970 10.1038/ncb1824 10.1158/1078-0432.CCR-1132-03 10.1200/JCO.2013.54.6911 10.1200/JCO.2002.20.1.289 10.1177/1756287215597647 10.1016/S0004-3702(97)00043-X 10.1038/ncomms3467 10.1016/j.juro.2010.06.105 10.1016/j.eururo.2011.05.028 10.1093/biomet/81.3.515 10.1063/1.4822879 10.1002/sim.4085 10.1371/journal.pbio.1001906 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 The Author(s). 2017 |
| Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 – notice: The Author(s). 2017 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12916-017-0874-9 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Databases Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 118 |
| ExternalDocumentID | oai_doaj_org_article_aa90bc574f0f41a1b1be9cae25200d23 A511362427 10_1186_s12916_017_0874_9 28648142 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Cancer Research UK – fundername: Medical Research Council grantid: MC_UU_12018/25 – fundername: ; – fundername: ; grantid: ETM37 – fundername: ; grantid: Clinical Training Fellowship – fundername: ; grantid: MC_UU_12018.25 – fundername: ; grantid: Robertson Trust – fundername: ; grantid: 50115 – fundername: ; grantid: Scottish Government Fellowship cofunded by Marie Curie Actions – fundername: ; grantid: Experimental Medicine Centre |
| GroupedDBID | --- -5E -5G -A0 -BR 0R~ 23N 2WC 3V. 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX CITATION AFGXO AFPKN 7QL 7U9 7XB 8FK AHSBF AZQEC C1K DWQXO H94 K9. M7N PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c591t-1fe9f8da531f7619b14d7db0c3dbab3b3ebb81ca81bc2da6cd833ee03f41f5963 |
| IEDL.DBID | RPM |
| ISSN | 1741-7015 |
| IngestDate | Tue Oct 22 15:14:01 EDT 2024 Tue Sep 17 21:05:01 EDT 2024 Fri Oct 25 22:52:42 EDT 2024 Thu Oct 10 22:12:23 EDT 2024 Tue Nov 19 20:06:46 EST 2024 Tue Nov 12 23:21:05 EST 2024 Tue Aug 20 22:10:11 EDT 2024 Fri Nov 22 03:05:42 EST 2024 Wed Oct 16 00:43:37 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prognostic markers Tumour biomarkers Tumour heterogeneity Renal cell carcinoma Cancer |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c591t-1fe9f8da531f7619b14d7db0c3dbab3b3ebb81ca81bc2da6cd833ee03f41f5963 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483837/ |
| PMID | 28648142 |
| PQID | 1915269778 |
| PQPubID | 42775 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_aa90bc574f0f41a1b1be9cae25200d23 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5483837 proquest_miscellaneous_1913833155 proquest_journals_1915269778 gale_infotracmisc_A511362427 gale_infotracacademiconefile_A511362427 gale_healthsolutions_A511362427 crossref_primary_10_1186_s12916_017_0874_9 pubmed_primary_28648142 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-26 |
| PublicationDateYYYYMMDD | 2017-06-26 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medicine |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2017 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | JF Deeken (874_CR37) 2015; 121 RF Sánchez-Ortiz (874_CR48) 2004; 171 DB Seligson (874_CR52) 2004; 10 GD Stewart (874_CR1) 2011; 8 KF Kerr (874_CR23) 2014; 25 GD Stewart (874_CR25) 2015; 21 WN Venables (874_CR28) 2010 WH Press (874_CR29) 1989; 3 S Gulati (874_CR39) 2014; 66 874_CR24 G Heppner (874_CR14) 1984; 44 MD Galsky (874_CR6) 2013; 14 S Vázquez (874_CR12) 2012; 29 XB Trinh (874_CR42) 2009; 100 M Laplante (874_CR41) 2012; 149 U Cavallaro (874_CR46) 2006; 312 RJ Motzer (874_CR9) 2009; 27 MJ Pencina (874_CR35) 2004; 23 D Maetzel (874_CR54) 2009; 11 BR Lane (874_CR38) 2015; 33 B Ljungberg (874_CR7) 2015; 67 AJ Pantuck (874_CR45) 2010; 70 X Taccoen (874_CR47) 2007; 51 A Marusyk (874_CR16) 2012; 12 874_CR5 M Trzpis (874_CR51) 2007; 171 R Fisher (874_CR40) 2013; 108 GD Stewart (874_CR19) 2015; 13 M Gerlinger (874_CR15) 2014; 46 OH Negm (874_CR36) 2016; 155 DY Heng (874_CR3) 2013; 14 GD Stewart (874_CR20) 2014; 66 M Jamal-Hanjani (874_CR55) 2014; 12 AO Pisco (874_CR31) 2013; 4 Y Benjamini (874_CR21) 2001; 29 DB Mendel (874_CR11) 2003; 9 EJ Abel (874_CR17) 2010; 184 R Kohavi (874_CR27) 1997; 97 T Powles (874_CR18) 2011; 60 PM Grambsch (874_CR33) 1994; 81 DYC Heng (874_CR49) 2009; 27 T Shimazui (874_CR44) 2006; 15 M Weinstock (874_CR13) 2015; 7 RJ Motzer (874_CR4) 2002; 20 RJ Motzer (874_CR43) 2014; 32 C Eichelberg (874_CR53) 2013; 132 MJ Pencina (874_CR22) 2011; 30 TM Mekhail (874_CR30) 2005; 23 D Cox (874_CR26) 1972; 34 RM Simon (874_CR34) 2009; 101 SE Kern (874_CR8) 2012; 72 G Spizzo (874_CR50) 2011; 64 RJ Motzer (874_CR10) 2007; 356 M Sun (874_CR2) 2011; 59 M Angelova (874_CR32) 2015; 16 |
| References_xml | – volume: 44 start-page: 2259 year: 1984 ident: 874_CR14 publication-title: Cancer Res contributor: fullname: G Heppner – volume: 27 start-page: 5794 year: 2009 ident: 874_CR49 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.21.4809 contributor: fullname: DYC Heng – volume: 23 start-page: 2109 year: 2004 ident: 874_CR35 publication-title: Stat Med doi: 10.1002/sim.1802 contributor: fullname: MJ Pencina – volume: 70 start-page: 752 year: 2010 ident: 874_CR45 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-2211 contributor: fullname: AJ Pantuck – volume: 27 start-page: 3584 year: 2009 ident: 874_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.1293 contributor: fullname: RJ Motzer – volume: 9 start-page: 327 year: 2003 ident: 874_CR11 publication-title: Clin Cancer Res contributor: fullname: DB Mendel – volume: 66 start-page: 936 year: 2014 ident: 874_CR39 publication-title: Eur Urol doi: 10.1016/j.eururo.2014.06.053 contributor: fullname: S Gulati – volume: 100 start-page: 971 year: 2009 ident: 874_CR42 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604921 contributor: fullname: XB Trinh – volume-title: Modern applied statistics with S year: 2010 ident: 874_CR28 contributor: fullname: WN Venables – volume: 356 start-page: 115 year: 2007 ident: 874_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa065044 contributor: fullname: RJ Motzer – volume: 46 start-page: 225 year: 2014 ident: 874_CR15 publication-title: Nat Genet doi: 10.1038/ng.2891 contributor: fullname: M Gerlinger – volume: 12 start-page: 323 year: 2012 ident: 874_CR16 publication-title: Nat Rev Cancer doi: 10.1038/nrc3261 contributor: fullname: A Marusyk – volume: 29 start-page: 1165 year: 2001 ident: 874_CR21 publication-title: Ann. Stat. doi: 10.1214/aos/1013699998 contributor: fullname: Y Benjamini – volume: 14 start-page: 141 year: 2013 ident: 874_CR3 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70559-4 contributor: fullname: DY Heng – volume: 155 start-page: 25 year: 2016 ident: 874_CR36 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-015-3654-2 contributor: fullname: OH Negm – volume: 34 start-page: 187 year: 1972 ident: 874_CR26 publication-title: J R Stat Soc B doi: 10.1111/j.2517-6161.1972.tb00899.x contributor: fullname: D Cox – volume: 101 start-page: 1446 year: 2009 ident: 874_CR34 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp335 contributor: fullname: RM Simon – volume: 67 start-page: 913 year: 2015 ident: 874_CR7 publication-title: Eur Urol doi: 10.1016/j.eururo.2015.01.005 contributor: fullname: B Ljungberg – volume: 51 start-page: 980 year: 2007 ident: 874_CR47 publication-title: Eur Urol doi: 10.1016/j.eururo.2006.10.025 contributor: fullname: X Taccoen – ident: 874_CR5 – volume: 312 start-page: 659 year: 2006 ident: 874_CR46 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2005.09.019 contributor: fullname: U Cavallaro – volume: 15 start-page: 1181 year: 2006 ident: 874_CR44 publication-title: Oncol Rep contributor: fullname: T Shimazui – volume: 64 start-page: 415 year: 2011 ident: 874_CR50 publication-title: J Clin Pathol doi: 10.1136/jcp.2011.090274 contributor: fullname: G Spizzo – volume: 29 start-page: 202 year: 2012 ident: 874_CR12 publication-title: Adv Ther doi: 10.1007/s12325-011-0099-9 contributor: fullname: S Vázquez – volume: 121 start-page: 1645 year: 2015 ident: 874_CR37 publication-title: Cancer doi: 10.1002/cncr.29224 contributor: fullname: JF Deeken – volume: 72 start-page: 6097 year: 2012 ident: 874_CR8 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-3232 contributor: fullname: SE Kern – volume: 33 start-page: 112.e15 year: 2015 ident: 874_CR38 publication-title: Urol Oncol Semin Orig Investig doi: 10.1016/j.urolonc.2014.11.009 contributor: fullname: BR Lane – volume: 14 start-page: 102 year: 2013 ident: 874_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70581-8 contributor: fullname: MD Galsky – volume: 13 start-page: 181 year: 2015 ident: 874_CR19 publication-title: Surgeon doi: 10.1016/j.surge.2015.03.001 contributor: fullname: GD Stewart – volume: 149 start-page: 274 year: 2012 ident: 874_CR41 publication-title: Cell doi: 10.1016/j.cell.2012.03.017 contributor: fullname: M Laplante – volume: 108 start-page: 479 year: 2013 ident: 874_CR40 publication-title: Br J Cancer doi: 10.1038/bjc.2012.581 contributor: fullname: R Fisher – volume: 59 start-page: 135 year: 2011 ident: 874_CR2 publication-title: Eur Urol doi: 10.1016/j.eururo.2010.10.029 contributor: fullname: M Sun – volume: 171 start-page: 2160 year: 2004 ident: 874_CR48 publication-title: J Urol doi: 10.1097/01.ju.0000125487.96469.2e contributor: fullname: RF Sánchez-Ortiz – ident: 874_CR24 doi: 10.3791/50221 – volume: 66 start-page: 956 year: 2014 ident: 874_CR20 publication-title: Eur Urol doi: 10.1016/j.eururo.2014.04.007 contributor: fullname: GD Stewart – volume: 21 start-page: 4212 year: 2015 ident: 874_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0207 contributor: fullname: GD Stewart – volume: 171 start-page: 386 year: 2007 ident: 874_CR51 publication-title: Am J Pathol doi: 10.2353/ajpath.2007.070152 contributor: fullname: M Trzpis – volume: 23 start-page: 832 year: 2005 ident: 874_CR30 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.179 contributor: fullname: TM Mekhail – volume: 8 start-page: 255 year: 2011 ident: 874_CR1 publication-title: Nat Rev Urol doi: 10.1038/nrurol.2011.43 contributor: fullname: GD Stewart – volume: 25 start-page: 114 year: 2014 ident: 874_CR23 publication-title: Epidemiology doi: 10.1097/EDE.0000000000000018 contributor: fullname: KF Kerr – volume: 16 start-page: 64 year: 2015 ident: 874_CR32 publication-title: Genome Biol doi: 10.1186/s13059-015-0620-6 contributor: fullname: M Angelova – volume: 132 start-page: 2948 year: 2013 ident: 874_CR53 publication-title: Int J Cancer J Int Cancer doi: 10.1002/ijc.27970 contributor: fullname: C Eichelberg – volume: 11 start-page: 162 year: 2009 ident: 874_CR54 publication-title: Nat Cell Biol doi: 10.1038/ncb1824 contributor: fullname: D Maetzel – volume: 10 start-page: 2659 year: 2004 ident: 874_CR52 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-1132-03 contributor: fullname: DB Seligson – volume: 32 start-page: 2765 year: 2014 ident: 874_CR43 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.54.6911 contributor: fullname: RJ Motzer – volume: 20 start-page: 289 year: 2002 ident: 874_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.1.289 contributor: fullname: RJ Motzer – volume: 7 start-page: 365 year: 2015 ident: 874_CR13 publication-title: Ther. Adv. Urol. doi: 10.1177/1756287215597647 contributor: fullname: M Weinstock – volume: 97 start-page: 273 year: 1997 ident: 874_CR27 publication-title: Artif Intell doi: 10.1016/S0004-3702(97)00043-X contributor: fullname: R Kohavi – volume: 4 start-page: 2467 year: 2013 ident: 874_CR31 publication-title: Nat Commun doi: 10.1038/ncomms3467 contributor: fullname: AO Pisco – volume: 184 start-page: 1877 year: 2010 ident: 874_CR17 publication-title: J Urol doi: 10.1016/j.juro.2010.06.105 contributor: fullname: EJ Abel – volume: 60 start-page: 448 year: 2011 ident: 874_CR18 publication-title: Eur Urol doi: 10.1016/j.eururo.2011.05.028 contributor: fullname: T Powles – volume: 81 start-page: 515 year: 1994 ident: 874_CR33 publication-title: Biometrika doi: 10.1093/biomet/81.3.515 contributor: fullname: PM Grambsch – volume: 3 start-page: 76 year: 1989 ident: 874_CR29 publication-title: Comput Phys doi: 10.1063/1.4822879 contributor: fullname: WH Press – volume: 30 start-page: 11 year: 2011 ident: 874_CR22 publication-title: Stat Med doi: 10.1002/sim.4085 contributor: fullname: MJ Pencina – volume: 12 start-page: e1001906 year: 2014 ident: 874_CR55 publication-title: PLoS Biol doi: 10.1371/journal.pbio.1001906 contributor: fullname: M Jamal-Hanjani |
| SSID | ssj0025774 |
| Score | 2.267283 |
| Snippet | Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for... Background Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well... BACKGROUNDMetastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as... Abstract Background Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 118 |
| SubjectTerms | Accuracy Adult Age Aged Algorithms Biomarkers Biomarkers, Tumor - genetics Cadherins Cancer Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - physiopathology Case reports Cell adhesion & migration Clear cell-type renal cell carcinoma Cohort Studies Confidence intervals Consortia Correlation coefficient Correlation coefficients Female Financing Genetic Heterogeneity Group dynamics Health risks Heterogeneity Humans Hypothesis testing Kidney cancer Kidney Neoplasms - genetics Kidney Neoplasms - pathology Kidney Neoplasms - physiopathology Male Mathematical models Medical prognosis Metastases Metastasis Middle Aged Morphology Multivariate analysis N-Cadherin Neoplasm Proteins Patients Performance prediction Prognosis Prognostic markers Proportional Hazards Models Protein Array Analysis Protein arrays Protein expression Proteins Quality Reclassification Renal cell carcinoma Replication Risk Risk groups Sampling Survival Survival Rate TOR protein Tumor markers Tumors Tumour biomarkers Tumour heterogeneity |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kD-JFfBtdtQVBEMKmH0l3e1vFZRFWLy7srelHhR10M7I7c_Dgf7eqkwwTPHjxNjNd00yqvpqq6lS-YuyN66wBBbkOyUGtlbbocz2-ElI20ToBkc4hz750p-f680V7sTfqi3rCRnrgUXFHIbgmptbovum1CCKKCC4FkMQXlOXI89nIuZiaSq0Ws5rpHqaw3dENRjVBlbOpG2t07RZRqJD1__2XvBeTlv2SewHo5B67O2WO_Hj8xffZLRgesNtn073xh-z3V0Ql4gdjEV_RDpstlvW4Eb-klpc1IgUw5eaYpXKisiSm11X8AfxqnpDLqc-cj0S6_XSW954HnjDS8cJDixvzuWuAf1_lAX7hKr67fsTOTz59-3haT8MV6tQ6salFD663OaAP9nSUEYXOJscmqRxDVFFBjFakgGltkjl0KVulABqFVuhbdNvH7GBYD_CUcQ3JQtuFbC0QO01AawvTu-BMMCbLir2ble1_jhwavtQetvOjZTxaxpNlvKvYBzLHTpDor8sHCAo_gcL_CxQVe0XG9OOzpDsn9sctjbDBrMRU7G2RIDdGtaYwPY2AV0SEWAvJw4Ukul9aLs-A8ZP733gsgmlyuzG2Yq93y_RNamkbYL0tMgpVivlcxZ6M-NpdtLSdtkKj5swCeQutLFeG1WUhB8cKlA4dnv0PNT5nd2Txma6W3SE72Fxv4QXmYJv4srjbH20VMqU priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Databases dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA96B-KL-G11agRBEMqapG0SX2STjSFsijjYW8hXt4vazvvx4IP_u-e0aV0RfLv3Jjc05yPnI6e_Q8hrXSsZRQy59TrmpSgV6FwDnxjnhVOaRYd5yJPT-vis_HhenaeE2zqVVY5nYn9Qh85jjnwP4gpshi2len_1M8euUXi7mlpo3CQ7nAmlFmTn4PD085cp5KrAu0l3mUzVe2uwbgwjaJkXSpa5nlmjHrT_36P5mm2a101eM0RHd8md5EHS_YHl98iN2N4nt07SHfkD8vsTSCfsCWwSXeIKmy2E97AQvcTSlw4kJoLrTcFbpQhpiYivS_c90h9jp1yK9eZ0ANRtUk7vHbXUg8WjPR4tLEzH6gH6bRna-AtG4dvqITk7Ovz64ThPTRZyX2m2yVkTdaOCBV1sMKXhWBlkcIUXwVknnIjOKeYtuLeeB1v7oISIsRBNyZoK1PcRWbRdG58QWkavYlXboFRElBoLXGey0VZLK2XgGXk7EttcDVgapo9BVG0GzhjgjEHOGJ2RA2THNBFhsPsfutWFSVplrNWF85UsmwIexzLHXNTeRo5gUoGLjLxEZprhndJJmc1-ha1swDuRGXnTz0B1BrJ6m95KgB0hMNZs5u5sJqihnw-PAmPSMbA2f4U2I6-mYfwnlra1sdv2cwSQFPy6jDwe5GvaNFd1qVgJlJMzyZtRZT7SLi97kHCIRDH58PT_j_WM3Oa9NtQ5r3fJYrPaxufgZW3ci6RKfwBLhisX priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF9qBfGl-G206gqCIESzH8nuCiJVLEU4ffGgb8t-xR7WXL3egX3wf3dmkxwNFt_ubjdLMjO_m5ndyW8IeWEarZJIsXTBpFIKqQFzLXxinFdeG5Y87kPOvjRHc_n5uD7eIWN7q0GA51emdthPar46ff3718V7APy7DHjdvDkHn8UwL1ZlpZUszTVynYNjxAqvmdweKoBxKjkcbF552cQ1ZQb_f_-nLzmqaRHlJa90eIvsDeEkPej1f5vspO4OuTEbDszvkj9fwVTBqMBB0QWusN5Arg8L0ROsg1mC-SSIwymErhT5LZH-deFPE_05ts2lWHxOe3bddtjge0sdDeD-aCanhYXpWEpAfyxily5gFL6t7pH54advH4_KoeNCGWrD1iVrk2l1dADMFvc3PJNRRV8FEb3zwovkvWbBQawbeHRNiFqIlCrRStbWgOX7ZLdbdukhoTIFnerGRa0TUtY4MAGmWuOMckpFXpBXo7DtWU-sYXNCohvba8aCZixqxpqCfEB1bCciJ3b-Ybn6bgeIWedM5UOtZFvB7TjmmU8muMSRWSpyUZBnqEzbv2C6RbY9qLGvDYQqqiAv8wy0NhBrcMMrCvBEyJI1mbk_mQmYDNPh0WDsaNIWMmNs566ULsjz7TBeiXVuXVpu8hwBIoUgryAPevvaPjTXjdRMguTUxPImUpmOdIuTzBgOaSnuRDz6_209Jjd5RkNT8maf7K5Xm_QEQq61f5qB9BfHEyyp priority: 102 providerName: Scholars Portal |
| Title | Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28648142 https://www.proquest.com/docview/1915269778 https://search.proquest.com/docview/1913833155 https://pubmed.ncbi.nlm.nih.gov/PMC5483837 https://doaj.org/article/aa90bc574f0f41a1b1be9cae25200d23 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB2MvY99z12UaDAYDN5YsW_LemtJSBulKWSHsRejLa1jjlDR56MP-993JdqjZ215MYp2Frbuf704-_UTIp6pUMuTBp8ZVIRW5UIC5Gn4xzjOrKhYszkNOz8uzK_FtVsx2SNGvhYlF-87OD5ubxWEzv461lbcLN-7rxMYX02OIsjGxGu-SXXC_fYreZVkFBDTd50umyvEdODSGSbNMMyVFijShXJVCMcEHvihS9v_7Yn7gmYZVkw_c0Okz8rSLH-lRe5_PyU5oXpDH0-4L-Uvy5zvYJlgReCQ6xx7WG0juoSN6jYUvS7CXAIE3hViVIqEl8r3O7U2gi36fXIrV5rSl0627Gb2v1FAH_o5GNlromPa1A_T33DfhHlrh3-oVuTo9-XF8lnZbLKSuqNg6ZXWoauUNILHGCQ3LhJfeZi731tjc5sFaxZyB4NZxb0rnVZ6HkOW1YHUB4H1N9pplE94SKoJToSiNVyogR40BnTNZV6aSRkrPE_KlH2x92zJp6JiBqFK3StKgJI1K0lVCJqiOrSCSYMcTy9Uv3ZmCNqbKrCukqDO4HcMss6FyJnCkkvI8T8gHVKZuV5RuoayPCtzIBmITmZDPUQLBDMPqTLcmAZ4IabEGkgcDSQChGzb3BqO7l8CdhlQY92-XUiXk47YZr8TCtiYsN1EGTDmHqC4hb1r72j50b6YJkQPLG4zKsAUQEynCO4Ts__eV78gTHjFTprw8IHvr1Sa8h_BrbUcAupkckUeTk_OLy1GcxIDjVCg4Xk5-jiIc_wI47zf7 |
| link.rule.ids | 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKwEXxJtAoUZCQkKKGsdJbHNBLWq1QHdBqJV6s_wKXQFJ2ceBA_-dmcRZGiFx2117rXgenocn3xDyUlVSBB58apwKacELCTpXwyeW55mVigWLecjZvJqeFR_Oy_OYcFvFssrhTOwOat86zJHvQ1yBzbCFkG8vf6bYNQpvV2MLjetkB5HTywnZOTyaf_6yDblK8G7iXSaT1f4KrBvDCFqkmRRFqkbWqAPt__dovmKbxnWTVwzR8R1yO3qQ9KBn-V1yLTT3yI1ZvCO_T35_AumEPYFNogtcYb2B8B4WohdY-tKCxARwvSl4qxQhLRHxdWG_B_pj6JRLsd6c9oC6dczpvaGGOrB4tMOjhYXpUD1Avy18E37BKHxbPiBnx0en76ZpbLKQulKxdcrqoGrpDehijSkNywovvM0c99ZYbnmwVjJnwL11uTeV85LzEDJeF6wuQX0fkknTNuExoUVwMpSV8VIGRKkxwHUmamWUMEL4PCGvB2Lryx5LQ3cxiKx0zxkNnNHIGa0Scojs2E5EGOzuh3b5VUet0saozLpSFHUGj2OYZTYoZ0KOYFI-5wnZQ2bq_p3SrTLrgxJb2YB3IhLyqpuB6gxkdSa-lQA7QmCs0czd0UxQQzceHgRGx2Ngpf8KbUJebIfxn1ja1oR2083hQFLw6xLyqJev7aZzWRWSFUA5MZK8EVXGI83iogMJh0gUkw9P_v9Ye-Tm9HR2ok_ezz8-JbfyTjOqNK92yWS93IRn4HGt7fOoVn8AaPIt_w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUXxJtAoUZCQkJKN46T2OFWCqvy2NIDlXqz_KQR3exqu3vgwH9nxklWG3HjtllPrMTzTWbGmXxDyJu6ksJz71Jta58WvJBgcwF-sTzPjKyZN7gPOTurTi-KL5fl5U6rr1i0b01z1F7Pj9rmKtZWLud2MtSJTc5nJxBlY2I1WbowuU3ulBxANiTqfa5VQljTv8RksprcgFtjmDqLNJOiSJEsNJdVIVmRjzxSJO7_9_G845_GtZM7zmh6n9zro0h63F3tA3LLtw_J_qx_T_6I_PkOCAUsgV-iDc6w3kCKDxPRKyx_WQBqPITfFCJWirSWyPramGtP50O3XIo157Qj1Q39vt57qqkFr0cjJy1MTIcKAvqrca3_DaNwtHpMLqaffpycpn2jhdSWNVunLPg6SKfBHgNuaxhWOOFMZrkz2nDDvTGSWQ0hrs2drqyTnHuf8VCwUIIJPyF77aL1zwgtvJW-rLST0iNTjQbNMxFqXQsthMsT8m5YbLXs-DRUzENkpTolKVCSQiWpOiEfUB1bQaTCjn8sVj9VDwildZ0ZW4oiZHA5mhlmfG21z5FQyuU8IYeoTNV9V7o1aHVcYjsbiFBEQt5GCTRpWFar-y8T4I6QHGskeTCSBFO04-EBMKp_FNwoSIixi7sQMiGvt8N4Jpa3tX6xiTIAaA6xXUKedvja3vQA04SIEfJGqzIeAbuJROG9nTz_7zMPyf75x6n69vns6wtyN4_mU6V5dUD21quNfwnx2Nq8ipb3FxwyNwQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overcoming+intratumoural+heterogeneity+for+reproducible+molecular+risk+stratification%3A+a+case+study+in+advanced+kidney+cancer&rft.jtitle=BMC+medicine&rft.au=Lubbock%2C+Alexander+L+R&rft.au=Stewart%2C+Grant+D&rft.au=OMahony%2C+Fiach+C&rft.au=Laird%2C+Alexander&rft.date=2017-06-26&rft.pub=BioMed+Central&rft.eissn=1741-7015&rft.volume=15&rft_id=info:doi/10.1186%2Fs12916-017-0874-9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |